Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases

<table class="table-group" id="tab7"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td align="left">Targets</td><td align="center">Drug</td><td align="center">Phase(s) trial</td><td align="center">Protocol_IDs*</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td align="left">BRAF and MEK for the MAPK pathway</td><td align="center">Sorafenib and Temsirolimus</td><td align="center">I, II</td><td align="center">NCT00349206</td></tr><tr><td align="left">PI3K, AKT and mTOR for the AKT/PI3K pathway</td><td align="center">MK2206 plus AZD6244</td><td align="center">I</td><td align="center">NCT01021748</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>
                *Clinical trials selected from <a href="http://mmdm.cancercommons.org/ml/index.php/A_Melanoma_Molecular_Disease_Model" target="_blank">http://mmdm.cancercommons.org/ml/index.php/A_Melanoma_Molecular_Disease_Model</a>.<br/></td></tr></table>

Dermatology Research and Practice

tab7

Table 7

Table 7: Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases 